AR068105A1 - Composiciones anhidras utiles para obtener un bienestar sexual mejorado - Google Patents
Composiciones anhidras utiles para obtener un bienestar sexual mejoradoInfo
- Publication number
- AR068105A1 AR068105A1 ARP080103644A ARP080103644A AR068105A1 AR 068105 A1 AR068105 A1 AR 068105A1 AR P080103644 A ARP080103644 A AR P080103644A AR P080103644 A ARP080103644 A AR P080103644A AR 068105 A1 AR068105 A1 AR 068105A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition according
- vasodilator
- group
- composition
- glycol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 13
- 230000001568 sexual effect Effects 0.000 title 1
- 229940124549 vasodilator Drugs 0.000 abstract 7
- 239000003071 vasodilator agent Substances 0.000 abstract 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 abstract 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 235000006708 antioxidants Nutrition 0.000 abstract 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 abstract 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 abstract 2
- 150000002814 niacins Chemical class 0.000 abstract 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- 150000005846 sugar alcohols Polymers 0.000 abstract 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 abstract 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 abstract 1
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 102100035792 Kininogen-1 Human genes 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000006 Nitroglycerin Substances 0.000 abstract 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 229960003711 glyceryl trinitrate Drugs 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 229940003183 hexalen Drugs 0.000 abstract 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 abstract 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 229960000201 isosorbide dinitrate Drugs 0.000 abstract 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 abstract 1
- 229960003827 isosorbide mononitrate Drugs 0.000 abstract 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 229960001789 papaverine Drugs 0.000 abstract 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 239000003507 refrigerant Substances 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960004559 theobromine Drugs 0.000 abstract 1
- 235000010384 tocopherol Nutrition 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 229960002381 vardenafil Drugs 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composicion anhidra que comprende un vasodilatador y un vehículo aceptable donde el vasodilatador está presente en una cantidad eficaz para aumentar el flujo sanguíneo cuando la composicion se aplica al tejido humano. Reivindicacion 4: Una composicion de acuerdo con la reivindicacion 1, donde dicha composicion está libre de un derivado de niacina. Reivindicacion 10: Una composicion de acuerdo con la reivindicacion 1, que además comprende un antioxidante en una cantidad eficaz para evitar la degradacion de dichos alcoholes polihídricos. Reivindicacion 11: Una composicion de acuerdo con la reivindicacion 10, donde dicho antioxidante se selecciona del grupo integrado por tocoferol, ácido ascorbico y hidroxitolueno butilado (BHT), donde dicho alcohol polihídrico se selecciona del grupo integrado por propilen glicol, polietilen glicol, polietilen glicol éteres, butiletilen glicol, hexalen glicol y combinaciones de tos mismos. Reivindicacion 16: Una composicion de acuerdo con la reivindicacion 15, donde dicho de mejorador de sensibilidad se selecciona de un compuesto refrigerante, un de calentamiento, un compuesto hormigueante, y mezclas de los mismos. Reivindicacion 48: Una composicion de acuerdo con a reivindicacion 47 donde dicho vasodilatador comprende un vasodilatador endogeno seleccionado del grupo integrado por oxido nítrico, histamina, prostaglandina D2, adenosina, L-arginina y bradiquinina. Reivindicacion 50: Una composicion de acuerdo con la reivindicacion 49 donde dicho vasodilatador exogeno comprende un inductor de oxido nítrico seleccionado del grupo integrado por nitrato de glicerilo (normalmente conocido como nitroglicerina), mononitrato isosorbide, dinitrato isosorbide, pentaeritrotol tetranitrato y nitropruside sodico. Reivindicacion 51: Una composicion de acuerdo con la reivindicacion 49 donde dicho vasodilatador exogeno comprende un inhibidor PDE5 seleccionado del grupo integrado por sildenafil, tadalafil, vardenafil, teobromina y papaverina. Reivindicacion 52: Una composicion de acuerdo con la reivindicacion 1 donde dicho vasodilatador se selecciona del grupo integrado por niacina y derivados de niacina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95708707P | 2007-08-21 | 2007-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068105A1 true AR068105A1 (es) | 2009-11-04 |
Family
ID=39967530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103644A AR068105A1 (es) | 2007-08-21 | 2008-08-21 | Composiciones anhidras utiles para obtener un bienestar sexual mejorado |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090197892A1 (es) |
| EP (2) | EP2027857A3 (es) |
| JP (1) | JP2009102303A (es) |
| KR (1) | KR20090019747A (es) |
| CN (1) | CN101549156A (es) |
| AR (1) | AR068105A1 (es) |
| AU (1) | AU2008207443A1 (es) |
| BR (1) | BRPI0806645A2 (es) |
| CA (1) | CA2638970A1 (es) |
| CL (1) | CL2008002466A1 (es) |
| CO (1) | CO6110129A1 (es) |
| MX (1) | MX2008010843A (es) |
| NZ (1) | NZ583456A (es) |
| RU (1) | RU2008134290A (es) |
| TW (1) | TW200927109A (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101666196B1 (ko) * | 2015-12-09 | 2016-10-14 | (주)아인스코퍼레이션 | 소취용 화장품 조성물 및 그 제조방법 |
| US20170239175A1 (en) * | 2016-02-19 | 2017-08-24 | FSD Pharma Co, LLC | Topical anorgasmia therapy |
| US10456401B2 (en) | 2017-05-12 | 2019-10-29 | Innovus Pharmaceuticals, Inc. | Therapeutic methods and compositions |
| US10758505B2 (en) | 2017-12-01 | 2020-09-01 | Innovus Pharmaceuticals, Inc. | Therapeutic compositions and methods |
| US20190167699A1 (en) | 2017-12-01 | 2019-06-06 | Innovus Pharmaceuticals, Inc. | Prostate function support formula |
| US10500199B2 (en) | 2017-12-01 | 2019-12-10 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for increasing cognitive functions |
| US10864205B2 (en) | 2017-12-01 | 2020-12-15 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for improving sexual health in men and women |
| US20230041289A1 (en) * | 2021-08-05 | 2023-02-09 | Innovus Pharmaceuticals, Inc. | Compositions and methods for enhancing or treating female sexual response |
| CN118576540A (zh) * | 2024-07-30 | 2024-09-03 | 杭州启真求实科技有限公司 | 一种用于男性勃起障碍外用的组合物凝胶及其制备方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2700043C2 (de) * | 1977-01-03 | 1983-12-08 | Thera Gesellschaft für Patentverwertung mbH, 8036 Herrsching | Mittel zur Verbesserung der Durchblutung und Wundheilung |
| GB2002233A (en) * | 1977-08-02 | 1979-02-21 | Champion J | Topical compositions containing vasodilators |
| DE3319282A1 (de) * | 1983-05-27 | 1984-11-29 | Gödecke AG, 1000 Berlin | Verwendung von adenosin bei der behandlung von herpes |
| US5208031A (en) * | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
| US5383848A (en) * | 1990-04-12 | 1995-01-24 | Gensia, Inc. | Iontophoretic administration of drugs |
| DE4117249C2 (de) * | 1991-05-27 | 1998-05-14 | Christian Dr Stief | Linsidomin zur Behandlung erektiler Dysfunktionen |
| BR9203277A (pt) * | 1992-08-21 | 1994-03-01 | Cesar Roberto Dias Nahoum | Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao |
| US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
| US6104225A (en) * | 1997-04-21 | 2000-08-15 | Fujitsu Limited | Semiconductor device using complementary clock and signal input state detection circuit used for the same |
| AU742787B2 (en) * | 1997-07-09 | 2002-01-10 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
| US7914814B2 (en) * | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
| US6593369B2 (en) * | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
| JP2001520999A (ja) * | 1997-10-28 | 2001-11-06 | アシビ， エルエルシー | 女性の性的機能不全の処置 |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US20040044080A1 (en) * | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| WO1999038472A2 (en) * | 1998-01-28 | 1999-08-05 | Seatrace Pharmaceuticals Inc | Topical vasodilatory gel composition and methods of use and production |
| US5891915A (en) * | 1998-05-01 | 1999-04-06 | Wysor; Michael S. | Method for enhancing female sexual response and an ointment therefor |
| US6436997B1 (en) * | 1998-06-01 | 2002-08-20 | Nitromed, Inc. | Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| US6428791B1 (en) * | 1999-04-13 | 2002-08-06 | Alphamed Pharmace Vticals, Corp | Lubrication composition |
| US20050100618A1 (en) * | 1999-07-01 | 2005-05-12 | Thompson Ronald J. | Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of Icariin, a herbal product produced from the Epimedium genus of the Berberidaceal family of plants, for the treatment of sexual dysfunction |
| US20020022052A1 (en) * | 2000-04-06 | 2002-02-21 | Dransfield Charles William | Transdermal delivery system |
| US20040137081A1 (en) * | 2003-01-13 | 2004-07-15 | Peter Rohdewald | Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins |
| ES2291333T3 (es) * | 2000-06-27 | 2008-03-01 | Qualilife Pharmaceuticals Inc. | Composiciones y metodos para el tratamiento de la respuesta sexual de las mujeres. |
| FR2812812B1 (fr) * | 2000-08-08 | 2002-10-11 | Philippe Gorny | Medicament destine notamment a combattre les dysfonctions sexuelles |
| US7128930B1 (en) * | 2000-09-01 | 2006-10-31 | Meir S. Sacks | Compositions and methods for treating sexual dysfunction |
| US6803060B2 (en) * | 2000-09-07 | 2004-10-12 | Joe Reyes | Composition to boost libido |
| US6403658B1 (en) * | 2000-09-21 | 2002-06-11 | Shaina Toppo | Genital vasodilator |
| US20020187165A1 (en) * | 2001-05-15 | 2002-12-12 | Joseph F. Long | Composition for female sexual arousal |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| GB0204919D0 (en) * | 2002-03-01 | 2002-04-17 | Cst Medical Ltd | Treatment of female sexual dysfunction |
| US7417013B2 (en) * | 2002-05-01 | 2008-08-26 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
| US7005408B2 (en) | 2002-05-01 | 2006-02-28 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
| US20040038984A1 (en) * | 2002-08-22 | 2004-02-26 | Harbeck Marie H. | Composition for male & female sexual arousal |
| US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
| US20040193452A1 (en) * | 2003-01-06 | 2004-09-30 | Laura Berman | Method and system for computerized sexual function assessment of female users |
| WO2004071437A2 (en) * | 2003-02-07 | 2004-08-26 | Barmensen, Inc. | Compositions for enhancing sexual responsiveness |
| US20040208902A1 (en) * | 2003-04-18 | 2004-10-21 | Gupta Shyam K. | Controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compositions |
| ITMI20031428A1 (it) * | 2003-07-11 | 2005-01-12 | Indena Spa | Combinazioni di agenti vasoattivi e loro uso per il trattamento di disfunzioni sessuali |
| US20060110415A1 (en) * | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
| US9173835B2 (en) * | 2005-05-10 | 2015-11-03 | Dermipsor Ltd. | Compositions and methods for treating hyperproliferative epidermal diseases |
| US7851419B2 (en) * | 2005-09-12 | 2010-12-14 | Nawaz Ahmad | Substantially anhydrous sprayable personal lubricant |
| US8668913B2 (en) * | 2007-02-09 | 2014-03-11 | Personal Products Company | Complementary personal lubricant compositions |
-
2008
- 2008-08-12 US US12/189,837 patent/US20090197892A1/en not_active Abandoned
- 2008-08-20 TW TW097131745A patent/TW200927109A/zh unknown
- 2008-08-20 EP EP08252766A patent/EP2027857A3/en not_active Withdrawn
- 2008-08-20 EP EP11191767A patent/EP2444089A3/en not_active Withdrawn
- 2008-08-20 NZ NZ583456A patent/NZ583456A/en not_active IP Right Cessation
- 2008-08-20 JP JP2008211909A patent/JP2009102303A/ja not_active Abandoned
- 2008-08-20 CA CA002638970A patent/CA2638970A1/en not_active Abandoned
- 2008-08-20 RU RU2008134290/15A patent/RU2008134290A/ru not_active Application Discontinuation
- 2008-08-21 CL CL2008002466A patent/CL2008002466A1/es unknown
- 2008-08-21 AR ARP080103644A patent/AR068105A1/es not_active Application Discontinuation
- 2008-08-21 KR KR1020080081964A patent/KR20090019747A/ko not_active Withdrawn
- 2008-08-21 AU AU2008207443A patent/AU2008207443A1/en not_active Abandoned
- 2008-08-21 CO CO08086986A patent/CO6110129A1/es not_active Application Discontinuation
- 2008-08-21 BR BRPI0806645-0A patent/BRPI0806645A2/pt not_active IP Right Cessation
- 2008-08-21 CN CNA2008101737414A patent/CN101549156A/zh active Pending
- 2008-08-21 MX MX2008010843A patent/MX2008010843A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008134290A (ru) | 2010-02-27 |
| NZ583456A (en) | 2011-09-30 |
| KR20090019747A (ko) | 2009-02-25 |
| AU2008207443A1 (en) | 2009-03-12 |
| CA2638970A1 (en) | 2009-02-21 |
| EP2444089A2 (en) | 2012-04-25 |
| MX2008010843A (es) | 2009-05-08 |
| CL2008002466A1 (es) | 2009-01-02 |
| US20090197892A1 (en) | 2009-08-06 |
| JP2009102303A (ja) | 2009-05-14 |
| EP2027857A3 (en) | 2009-04-29 |
| EP2444089A3 (en) | 2012-08-29 |
| CN101549156A (zh) | 2009-10-07 |
| BRPI0806645A2 (pt) | 2009-12-01 |
| TW200927109A (en) | 2009-07-01 |
| CO6110129A1 (es) | 2009-12-31 |
| EP2027857A2 (en) | 2009-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068105A1 (es) | Composiciones anhidras utiles para obtener un bienestar sexual mejorado | |
| ES2548998T3 (es) | Composiciones antifúngicas de azol | |
| PL193464B1 (pl) | Zastosowanie inhibitora białkowej transferazy farnezylowej | |
| BR0316595A (pt) | Composto, método para a preparação de compostos, composição farmacêutica e usos do composto | |
| CU24316B1 (es) | Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| PE20051137A1 (es) | Compuestos de 5,6-dialquil-7-amino-triazolopirimidinas y procedimientos de preparacion | |
| CY1113060T1 (el) | Συνθεση αφρου πιμεκρολιμους που περιεχει εξυλενογλυκολη, προαιρετικα ελαϊκη αλκοολη, διμεθυλισοσορβιδη και/ή μεσης αλυσιδας τριγλυκεριδια | |
| PA8593001A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| ECSP045391A (es) | Derivados de triazol como antagonistas de receptor de taquicinina | |
| NZ625593A (en) | Purine derivatives useful as hsp90 inhibitors | |
| CA2449031A1 (en) | Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture | |
| ES2822081T3 (es) | Intermediario de voriconazol y método de síntesis de voriconazol | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| HUT64331A (en) | Methods for producing (2-imidazoline-2-yl-amino)-quinoxaline derivatives and medical preparatives containing them | |
| JP2023154054A5 (es) | ||
| MX2024011130A (es) | Inhibidor de derivados heterociclicos que contienen nitrogeno, metodo de preparacion y utilizacion del mismo | |
| PE20020997A1 (es) | Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar padecimientos | |
| AR041626A1 (es) | Compuestos derivados de benzimidazol utilizables para el tratamiento del dolor y de enfermedades. | |
| ES8300711A1 (es) | Un procedimiento para la preparacion de un derivado cis-4,5-disustituidos de imidazolidin-2-ona opticamente activo. | |
| RU2009129231A (ru) | Взрывчатая композиция многофункционального действия | |
| CL2022003400A1 (es) | Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette | |
| HU184787B (en) | Process for preparing alkoxy-benzyl-pyrido-pyrimidine derivatives | |
| CA2973326C (en) | Tocopherol stabilisers for nitrocellulose-based propellants | |
| MX2025000791A (es) | Compuestos terapeuticos, formulaciones y uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |